Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Modified P200TE Data Collection

NCT07796230 · tracked via the Priya Life Science USA tracker
Sponsor
Optos, PLC
Phase
Observational
Started
2026-07-29
Last updated
2026-09-01

Condition(s) studied

Retina Disease

Investigational drug(s) / intervention(s)

imaging device

imaging device: images captured on a modified P200TE

Study summary

Images will be collected on the modified P200TE

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria Male or female participants 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed Participants who can follow the instructions by the clinical staff at the clinical site Participants who agree to participate in the study Participants with posterior segment eye disease. Example of pathologies may include but are not limited to Age-related macular degeneration, glaucoma, diabetic retinopathy, posterior uveitis, central serous chorioretinopathy, vein occlusion, epiretinal membrane and others as confirmed by the investigator. Exclusion Criteria Participants unable to tolerate ophthalmic imaging. Participants with ocular media not sufficiently clear to obtain acceptable images. Unable to obtain acceptable image quality on participant.

Primary outcome measure(s)

  • Number of images — 1 year

Trial sites (1)

FacilityCityRegionStatus
Bennett & Bloom Eye Centers Louisville Kentucky Recruiting

More Optos, PLC trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07796230 on ClinicalTrials.gov ↗ ← All trials in the USA